Detection of postvaccination mumps virus antibody by neutralization test, enzyme-linked immunosorbent assay and sensitive hemagglutination inhibition test.
A group of 251 children aged 2-3 years given live attenuated mumps virus vaccine PAVIVAC of Czechoslovak production were tested for antiparotitis antibody levels in pre- and postvaccination sera by neutralization test (NT), enzyme-linked immunosorbent assay (ELISA) and sensitive hemagglutination inhibition test, enhanced by heterologous antibody to human immunoglobulin G (E-HIT). The prevaccination findings were as follows: positive ELISA IgG titres, neutralization antibodies and hemagglutination inhibition antibodies were present in, respectively, 35%, 25.9% and 27.9% of the sera. Postvaccination seroconversions were evaluated in 159 susceptible vaccinees whose prevaccination sera had been negative by all three tests. The lowest seroconversion was detected by NT (74.2%), seroconversions by ELISA and E-HIT were appreciably higher (82.4% and 86.8%, respectively). The seven children showing a seroconversion by E-HIT but not by ELISA had a 4 fold increase of anti-mumps ELISA IgG antibodies as well, but the rise of antibody titres was at a level falling in the range below the positivity criterion for ELISA. The statistically evaluated detection rate for antibodies was significantly higher (significance test "t") by ELISA as compared with neutralization test. However, antibody levels (geometric mean titres) were 8-10 times lower in postvaccination sera than in convalescent sera of 30 children with mumps in all three tests.
Institute of Hygiene and Epidemiology, Prague, Czechoslovakia.
D
D
Fedová
M
M
Brůcková
V
V
Plesník
D
D
Slonim
J
J
Sejda
E
E
Svandová
I
I
Kubínová
D000914:Antibodies, Viral / Q000032:analysis* / Q000096:biosynthesis; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005069:Evaluation Studies as Topic; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D009108:Mumps Vaccine / Q000276:immunology* / Q000627:therapeutic use; D009109:Mumps virus / Q000276:immunology*; D009500:Neutralization Tests; D014613:Vaccines, Attenuated / Q000276:immunology / Q000627:therapeutic use
D000914:Antibodies, Viral; D009108:Mumps Vaccine; D014613:Vaccines, Attenuated